$1.71
3.93% yesterday
Nasdaq, Jun 11, 10:10 pm CET
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

MacroGenics, Inc. Stock price

$1.71
+0.12 7.55% 1M
-1.70 49.85% 6M
-1.54 47.38% YTD
-3.22 65.31% 1Y
-18.11 91.37% 5Y
-32.03 94.93% 10Y
-23.28 93.16% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.07 3.93%
ISIN
US5560991094
Symbol
MGNX
Sector
Industry

Key metrics

Market capitalization $107.88m
Enterprise Value $-46.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.64
EV/Sales (TTM) EV/Sales -0.30
P/S ratio (TTM) P/S ratio 0.70
P/B ratio (TTM) P/B ratio 1.36
Revenue growth (TTM) Revenue growth 255.61%
Revenue (TTM) Revenue $154.05m
EBIT (operating result TTM) EBIT $-63.20m
Free Cash Flow (TTM) Free Cash Flow $-72.40m
Cash position $154.14m
EPS (TTM) EPS $-0.89
P/E forward negative
P/S forward 1.18
EV/Sales forward negative
Short interest 11.89%
Show more

Is MacroGenics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,840 stocks worldwide.

MacroGenics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a MacroGenics, Inc. forecast:

2x Buy
29%
5x Hold
71%

Analyst Opinions

7 Analysts have issued a MacroGenics, Inc. forecast:

Buy
29%
Hold
71%

Financial data from MacroGenics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
154 154
256% 256%
100%
- Direct Costs 16 16
126% 126%
10%
138 138
279% 279%
90%
- Selling and Administrative Expenses 67 67
26% 26%
44%
- Research and Development Expense 171 171
3% 3%
111%
-56 -56
131% 131%
-36%
- Depreciation and Amortization 7.47 7.47
12% 12%
5%
EBIT (Operating Income) EBIT -63 -63
94% 94%
-41%
Net Profit -56 -56
141% 141%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about MacroGenics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MacroGenics, Inc. Stock News

Neutral
Seeking Alpha
about 12 hours ago
I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with key phase 2 data expected in late 2025, and additional programs like MGC-026 and MGC-028 progressing. The recent royalty deal extends the cash runway, but liquidity concerns remain, and further asset...
Neutral
GlobeNewsWire
2 days ago
MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics' cash runway extended through first half of 2027 ROCKVILLE, MD, June 10, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for th...
Neutral
GlobeNewsWire
9 days ago
ROCKVILLE, MD, June 03, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 on Tue...
More MacroGenics, Inc. News

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Head office United States
CEO Scott Koenig
Employees 341
Founded 2000
Website www.macrogenics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today